In conclusion, there is extensive experimental evidence that NLRP3 inhibitors can modulate NLRP3 inflammasome activation to prevent or treat AD and PD; therefore, it would be of great value to discover various NLRP3 modulators and use them to develop new therapeutic strategies for treating neurodegenerative diseases. This evidence concerns the gene NLRP3 and neurodegenerative disease.